Head and neck radiotherapy worsens long-term oral health despite structured dental follow-up
After head and neck RT, 43% of patients lost teeth and higher oral cavity dose was associated with tooth loss.
Tag
Worth Attention
Anal cancer targets changed substantially during chemoradiotherapy despite standard PTV margins
Across 212 CBCTs, 36.8% showed target extensions >10 mm beyond the planning PTV despite progressive overall CTV shrinkage.
Short- and long-course rectal RT produced similar patient-reported outcomes by two years
Long-course chemoradiation caused greater preoperative symptom burden, but patient-reported bowel, urinary and overall outcomes converged after surgery.
ALLSTAR confirmed durable Durvalumab benefit while high-dose RT showed a thoracic-control signal
Durvalumab after CRT improved long-term outcomes in stage III NSCLC, while dose escalation above 66 Gy showed only exploratory intrathoracic benefit.
Unilateral RT produced no contralateral neck failures in N2b oropharyngeal cancer
No contralateral neck recurrences occurred among 43 N2b patients receiving unilateral RT despite frequent high ipsilateral nodal burden.
Higher SMAD4 expression tracked with fewer distant failures after resected pancreatic cancer
Higher tumor SMAD4 was associated with better disease-free survival and lower distant metastatic risk after resection and adjuvant chemoradiotherapy.
Repeated TURP predicted late urinary toxicity more strongly than focal prostate dose escalation
After prior TURP, focal SIB was not significantly associated with severe late GU toxicity, while repeated TURP consistently identified higher-risk patients.
Prostate motion during online adaptation supports routine verification before treatment
Across 1,378 adaptive fractions, 4.6% had shifts above 6 mm and longer adaptation times were linked to greater prostate displacement.
EPTN marks a decade of European particle therapy collaboration and sets its next priorities
After 10 years, EPTN is shifting its focus toward prospective registries, adaptive therapy, harmonised QA and stronger clinical evidence.
Rectal retractors reduced rectal dose but increased bladder dose in cervical brachytherapy
Rectal retractor use lowered rectal D2cc and was associated with fewer grade ≥2 vaginal adverse events without reducing target coverage.
Paclitaxel-based trimodality therapy shows promising control but substantial toxicity in cutaneous angiosarcoma
In a small phase II study, induction and concurrent paclitaxel with RT, usually followed by surgery, achieved 82.5% two-year PFS in cutaneous angiosarcoma. Grade 3+ acute and late toxicity occurred in 58% and 32%, respectively.
Very late toxicities emerged more than a decade after stage I lung SBRT
Ten-year lung SBRT survivors developed rare airway, chest-wall and pericardial toxicities, while no local failures occurred beyond year 10.
Neoadjuvant ADT obscured 40% of MRI-visible prostate lesions before focal boost
After neoadjuvant ADT, 40% of MRI-visible prostate lesions disappeared and remaining lesions shrank substantially more than the prostate gland.
Breast skin V40 predicted lymphedema after breast-conserving therapy
Skin V40 >90 cc nearly quadrupled breast lymphedema odds, while mammographic skin thickening provided an objective detection signal.
Short-course RT increases complete response when added to immunochemotherapy in pMMR rectal cancer
In randomized TORCH-iTNT, adding 25 Gy in 5 fractions before CAPOX plus toripalimab increased complete response from 37.1% to 61.5% in pMMR locally advanced rectal cancer. Long-term outcomes remain pending.